The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Dorofeĭkova M.V.

Kafedra psikhiatrii i narkologii meditsinskogo fakul'teta Sankt-Peterburgskogo gosudarstvennogo universiteta, Sankt-Peterburg

Petrova N.N.

Saint-Petersburg State University, Saint-Petersburg, Russia

The effectiveness and feasibility of preventive interventions for psychoses

Authors:

Dorofeĭkova M.V., Petrova N.N.

More about the authors

Read: 831 times


To cite this article:

Dorofeĭkova MV, Petrova NN. The effectiveness and feasibility of preventive interventions for psychoses. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(8):108‑112. (In Russ.)
https://doi.org/10.17116/jnevro2019119081108

Recommended articles:
The rela­tionship of diet and nutrition with the frequency of migraine atta­cks. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):30-35
Analysis of medi­cal preventive stru­ctures staff resources in 2023. Russian Journal of Preventive Medi­cine. 2024;(10):45-51
Study of opinions of medi­cal students on medi­cal prevention issues. Russian Journal of Preventive Medi­cine. 2024;(12):69-74
Gastric cancer: inci­dence, risk factors, screening. Russian Journal of Preventive Medi­cine. 2024;(12):135-139
Obstructive sleep apnea syndrome as a predictor of atrial fibrillation. Russian Journal of Preventive Medi­cine. 2025;(1):109-114
Vita­min D role in oral cavity diseases. Stomatology. 2025;(1):81-86

References:

  1. Addington J, Addington D, Abidi S, Raedler T, Remington G. Canadian Treatment Guidelines for Individuals at Clinical High Risk of Psychosis. Can J Psychiatry. 2017;62(9):656-661. https://doi.org/10.1177/0706743717719895
  2. Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell’Olio M, Francey SM, Cosgrave EM, Killackey E, Stanford C, Godfrey K, Buckby J. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry. 2005;39(11-12):964-971. https://doi.org/10.1080/j.1440-1614.2005.01714.x
  3. Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull. 2009;35(1):5-8. https://doi.org/10.1093/schbul/sbn139
  4. Schultze-Lutter F, Michel C, Schmidt SJ, Schimmelmann BG, Maric NP, Salokangas RK, Riecher-Rössler A, van der Gaag M, Nordentoft M, Raballo A, Meneghelli A, Marshall M, Morrison A, Ruhrmann S, Klosterkötter J. EPA guidance on the early detection of clinical high risk states of psychoses. Eur Psychiatry. 2015;30(3):405-416. https://doi.org/10.1016/j.eurpsy.2015.01.010
  5. Riecher-Rössler A, Studerus E. Prediction of conversion to psychosis in individuals with an at-risk mental state: a brief update on recent developments. Curr Opin Psychiatry. 2017;30(3):209-219. https://doi.org/10.1097/YCO.0000000000000320
  6. Millan MJ, Andrieux A, Bartzokis G, Cadenhead K, Dazzan P, Fusar-Poli P, Gallinat J, Giedd J, Grayson DR, Heinrichs M, Kahn R, Krebs MO, Leboyer M, Lewis D, Marin O, Marin P, Meyer-Lindenberg A, McGorry P, McGuire P, Owen MJ, Patterson P, Sawa A, Spedding M, Uhlhaas P, Vaccarino F, Wahlestedt C, Weinberger D. Altering the course of schizophrenia: progress and perspectives. Nat Rev Drug Discov. 2016;15(7):485-515. https://doi.org/10.1038/nrd.2016.28
  7. Carrión RE, Demmin D, Auther AM, McLaughlin D, Olsen R, Lencz T, Correll CU, Cornblatta BA. Duration of attenuated positive and negative symptoms in individuals at clinical high risk: Associations with risk of conversion to psychosis and functional outcome. J Psychiatr Res. 2016;81:95-101. https://doi.org/10.1016/j.jpsychires.2016.06.021
  8. Rüsch N, Müller M, Heekeren K, Theodoridou A, Metzler S, Dvorsky D, Corrigan PW, Walitza S, Rössler W. Longitudinal course of self-labeling, stigma stress and well-being among young people at risk of psychosis. Schizophr Res. 2014;158(1-3):82-84. https://doi.org/10.1016/j.schres.2014.07.016
  9. Granö N, Karjalainen M, Edlund V, Saari E, Itkonen A, Anto J, Roine M. Health-related quality of life among adolescents: a comparison between subjects at risk for psychosis and other help seekers. Early Interv Psychiatry. 2014;8(2):163-169. https://doi.org/10.1111/eip.12033
  10. Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, Maric NP, Salokangas RK, Riecher-Rössler A, van der Gaag M, Meneghelli A, Nordentoft M, Marshall M, Morrison A, Raballo A, Klosterkötter J, Ruhrmann S. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry. 2015;30(3):388-404. https://doi.org/10.1016/j.eurpsy.2015.01.013
  11. McGorry PD, Mei C. Ultra-high-risk paradigm: lessons learnt and new directions. Evid Based Ment Health. 2018;21(4):131-133. https://doi.org/10.1136/ebmental-2018-300061
  12. Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, Howes O, Stieglitz RD, Vita A, McGuire P, Borgwardt S. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry. 2012;69(6):562-571. https://doi.org/10.1001/archgenpsychiatry.2011.1592
  13. Thompson A, Papas A, Bartholomeusz C, Allott K, Amminger GP, Nelson B, Wood S, Yung A. Social cognition in clinical «at risk» for psychosis and first episode psychosis populations. Schizophr Res. 2012;141(2-3):204-209. https://doi.org/10.1016/j.schres.2012.08.007
  14. Carrión RE, McLaughlin D, Goldberg TE, Auther AM, Olsen RH, Olvet DM, Correll CU, Cornblatt BA. Prediction of functional outcome in individuals at clinical high risk for psychosis. JAMA Psychiatry. 2013;70(11):1133-1142. https://doi.org/10.1001/jamapsychiatry.2013.1909
  15. Schultze-Lutter F, Schmidt SJ, Walger P, Schimmelmann BG. Developmental Aspects in the Early Detection and Intervention in Clinical High Risk States for Psychosis. Prax Kinderpsychol Kinderpsychiatr. 2017;66(5):324-344. https://doi.org/10.13109/prkk.2017.66.5.324
  16. Penno SJ, Hamilton B, Petrakis M. Early Intervention in Psychosis: Health of the Nation Outcome Scales (HoNOS) Outcomes From a Five-Year Prospective Study. Archives of Psychiatric Nursing. 2007;31(6):553-560. https://doi.org/10.1016/j.apnu.2017.07.003
  17. White DA, Luther L, Bonfils KA, Salyers MP. Essential components of early intervention programs for psychosis: Available intervention services in the United States. Schizophrenia Research. 2015;168(1-2):79-83. https://doi.org/10.1016/j.schres.2015.08.020
  18. Cornblatt BA, Carrión RE, Auther A, McLaughlin D, Olsen RH, John M, Correll CU. Psychosis Prevention: A Modified Clinical High Risk Perspective From the Recognition and Prevention (RAP) Program. Am J Psychiatry. 2015;172(10):986-994. https://doi.org/10.1176/appi.ajp.2015.13121686
  19. Qurashi I, Chaudhry IB, Khoso AB, Farooque S, Lane S, Husain MO, Chu S, Sarginson J, Hamarani M, Naqvi HA, Razzaque B, Minhas FA, Yung AR, Deakin JFW, Husain N. A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol. Trials. 2017;18:524. https://doi.org/10.1186/s13063-017-2275-y
  20. Washida K, Takeda T, Habara T, Sato S, Oka T, Tanaka M, Yoshimura Y, Aoki S. Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophrenia. Neuropsychiatr Dis Treat. 2013;9:861-868. https://doi.org/10.2147/NDT.S45697
  21. Waite F, Bradley J, Chadwick E, Reeve S, Bird JC, Freeman D. The Experience of Sleep Problems and Their Treatment in Young People at Ultra-High Risk of Psychosis: A Thematic Analysis. Front Psychiatry. 2018;9:375. https://doi.org/10.3389/fpsyt.2018.00375
  22. Cornblatt BA, Lencz T, Smith CW, Olsen R, Auther AM, Nakayama E, Lesser ML, Tai JY, Shah MR, Foley CA, Kane JM, Correll CU. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry. 2007;68:546-557.
  23. Kelly DL, Conley RR, Carpenter WT. First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs. 2005;65(8):1113-1138. https://doi.org/10.2165/00003495-200565080-00006
  24. Liu CC, Demjaha A. Antipsychotic interventions in prodromal psychosis: safety issues. CNS Drugs. 2013;27(3):197-205. https://doi.org/10.1007/s40263-013-0046-1
  25. Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Chaimani A, Leucht S. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. Eur Neuropsychopharmacol. 2018;28(6):659-674. https://doi.org/10.1016/j.euroneuro.2018.03.008
  26. Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B, Monaco F, Vieta E, Seeman MV, Correll CU, Carvalho AF. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757-777. https://doi.org/10.2147/TCRM.S117321

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.